Omnicell (NASDAQ:OMCL) Downgraded by StockNews.com to “Hold”

Omnicell (NASDAQ:OMCL) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Several other equities analysts also recently weighed in on the company. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Benchmark reissued a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a research report on Monday, July 15th. Bank of America boosted their target price on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Wells Fargo & Company boosted their price objective on Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Omnicell currently has a consensus rating of “Hold” and a consensus price target of $37.83.

Omnicell Price Performance

OMCL stock opened at $42.78 on Thursday. The company has a fifty day simple moving average of $38.52 and a two-hundred day simple moving average of $32.04. Omnicell has a 52 week low of $25.12 and a 52 week high of $56.05. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $1.97 billion, a P/E ratio of -93.00, a price-to-earnings-growth ratio of 47.22 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. During the same quarter last year, the firm earned $0.29 EPS. The firm’s revenue for the quarter was down 7.4% compared to the same quarter last year. Analysts anticipate that Omnicell will post 0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Algert Global LLC lifted its holdings in shares of Omnicell by 9.8% in the 2nd quarter. Algert Global LLC now owns 51,942 shares of the company’s stock worth $1,406,000 after buying an additional 4,617 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Omnicell by 6.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company’s stock worth $635,000 after acquiring an additional 1,360 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in Omnicell by 238.4% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 31,474 shares of the company’s stock valued at $852,000 after purchasing an additional 22,174 shares during the period. AQR Capital Management LLC raised its holdings in shares of Omnicell by 10.3% in the 2nd quarter. AQR Capital Management LLC now owns 49,071 shares of the company’s stock valued at $1,328,000 after purchasing an additional 4,572 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Omnicell during the second quarter valued at approximately $1,623,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.